Feasibility of Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02628899 |
Recruitment Status :
Active, not recruiting
First Posted : December 11, 2015
Last Update Posted : December 17, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Aortic Stenosis | Device: Transfemoral TAVR Device: SAVR | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Study Start Date : | January 2016 |
Estimated Primary Completion Date : | January 2023 |
Estimated Study Completion Date : | January 2023 |

Arm | Intervention/treatment |
---|---|
Prospective TAVR Arm
200 patients prospectively undergoing transfemoral TAVR
|
Device: Transfemoral TAVR
Other Name: Transcatheter aortic valve replacement |
Historical SAVR Controls
Historical controls will be selected from among patients at the same site who have undergone isolated bioprosthetic SAVR within the previous 36 months. TAVR patients will then be matched to SAVR patients using STS database variables to perform propensity matching, including (but not limited to) age, gender, race, ethnicity, STS score, and valve prosthesis size.
|
Device: SAVR
Other Name: Surgical Aortic Valve Replacement |
Low-Risk TAVR with Bicuspid Aortic Valve
The third arm of the trial will comprise a registry of TAVR in up to 100 low-risk patients with bicuspid aortic valve. The results from the registry arm will be analyzed independently.
|
Device: Transfemoral TAVR
Other Name: Transcatheter aortic valve replacement |
- All-cause mortality at 30 days following transfemoral TACR vs. bioprosthetic SAVR [ Time Frame: 30 days following transfemoral TAVR vs. bioprosthetic SAVR ]All-cause mortality at 30 days following transfemoral TACR vs. bioprosthetic SAVR
- Composite of major adverse events at 30 days [ Time Frame: 30 days ]
Composite of major adverse events at 30 days
- all-cause mortality
- stroke
- spontaneous myocardial infarction (MI)
- reintervention: defined as any cardiac surgery or percutaneous reintervention that repairs, alters, or replaces a previously implanted aortic valve
- VARC life-threatening bleeding
- Increase in serum creatinine to ≥300% (>3x increase compared to baseline) OR serum creatinine ≥4.0 mg/dL with an acute increase ≥0.5 mg/dL OR new requirement for dialysis
- coronary artery obstruction requiring percutaneous or surgical intervention
- VARC major vascular complication
- cardiac tamponade
- cardiac perforation
- pericarditis
- mediastinitis
- hemolysis
- infective endocarditis
- moderate or severe aortic insufficiency
- significant aortic stenosis
- permanent pacemaker implantation
- All Cause Mortality [ Time Frame: 30 days ]
- All Stroke (disabling and non-disabling, ischemic and hemorrhagic [ Time Frame: 30 Days ]
- Life Threatening and Major Bleeding [ Time Frame: 30 days ]
- Major Vascular Complications [ Time Frame: 30 days ]
- Hospitalizations for valve-related symptoms or worsening congestive heart failure [ Time Frame: 30 days ]
- composite of all-cause mortality, stroke, spontaneous MI, re-intervention [ Time Frame: 30 days, 6 months, 12 months, and 2,3,4 and 5 years ]
composite of:
- all-cause mortality
- stroke
- spontaneous MI
- re-intervention 2. The occurrence of the individual components of MACCE at 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years. 3. The composite of major adverse device events post-procedure, and at 6 months, 1 year, and 2, 3, 4, 5 years 4. VARC major vascular complications, at 30 days and 1 year 5. VARC life-threatening or disabling bleeding, at 30 days and 1 year 6. Assessment for subclinical leaflet thrombosis with multislice computed tomography, or transesophageal echocardiography if GFR <50 mL/min/m2, at 1 to 2 months.
- VARC - 2 Device Success [ Time Frame: 30 days ]Absence of procedural mortality AND Correct positioning of a single prosthetic heart valve into the proper anatomical location AND Intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient<20 mm Hg or peak velocity<3 m/s, AND no moderate or severe prosthetic valve regurgitation)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Severe, degenerative AS, defined as:
- mean aortic valve gradient ≥40 mm Hg OR Vmax ≥4 m/sec AND
- calculated aortic valve area ≤1.0 cm2 OR aortic valve area index ≤0.6 cm2/m2
-
Symptomatic AS, defined as a history of at least one of the following:
- dyspnea that qualifies at New York Heart Association (NYHA) class II or greater
- angina pectoris
- cardiac syncope
- The Heart Team, including at least one cardiothoracic surgeon and one interventional cardiologist, deem the patient to be reasonable for transfemoral TAVR with a commercially available bioprosthetic valve
- The Heart Team agrees that the patient is low-risk, quantified by an estimated risk of ≤3% by the calculated STS score for operative mortality at 30 days; AND agrees that SAVR would be an appropriate therapy if offered.
- The Heart Team agrees that transfemoral TAVR is anatomically feasible, based upon multislice CT measurements
- Procedure status is elective
-
Expected survival is at least 24 months
For the bicuspid cohort only:
- Aortic Stenosis of a bicuspid aortic valve
Exclusion Criteria:
- Concomitant disease of another heart valve or the aorta that requires either transcatheter or surgical intervention
- Any condition that is considered a contraindication for placement of a bioprosthetic aortic valve (e.g. patient requires a mechanical aortic valve)
- Aortic stenosis secondary to a bicuspid aortic valve (except for the bicuspid valve cohort)
- Prior bioprosthetic surgical aortic valve replacement
- Mechanical heart valve in another position
- End-stage renal disease requiring hemodialysis or peritoneal dialysis, or a creatinine clearance <20 cc/min
- Left ventricular ejection fraction <20%
- Recent (<6 months) history of stroke or transient ischemic attack
- Symptomatic carotid or vertebral artery disease, or recent (<6 weeks) surgical or endovascular treatment of carotid stenosis
- Any contraindication to oral antiplatelet or anticoagulation therapy following the procedure, including recent or ongoing bleeding, or HASBLED score >3
- Severe coronary artery disease that is unrevascularized
- Recent (<30 days) acute myocardial infarction
- Patient cannot undergo transfemoral TAVR for anatomic reasons (as determined by supplemental imaging studies); this would include inadequate size of iliofemoral access vessels or an aortic annulus size that is not accommodated by the commercially available valves
-
Any comorbidity not captured by the STS score that would make SAVR high risk, as determined by a cardiothoracic surgeon who is a member of the heart team; this includes:
- porcelain or severely atherosclerotic aorta
- frailty
- hostile chest
- IMA or other conduit either crosses midline of sternum or is adherent to sternum
- severe pulmonary hypertension (PA systolic pressure > 2/3 of systemic pressure)
- severe right ventricular dysfunction
- Ongoing sepsis or infective endocarditis
- Recent (<30 days) or ongoing bleeding that would preclude treatment with anticoagulant or antiplatelet therapy, including recent gastrointestinal bleeding
- Uncontrolled atrial fibrillation (resting heart rate >120 beats per minute)
- Severe chronic obstructive pulmonary disease, as demonstrated by forced expiratory volume (FEV1) <750 cc
- Liver failure with Childs class C or D
- Pre-procedure shock, inotropes, mechanical assist device, or cardiac arrest
- Pregnancy or intent to become pregnant prior to completion of all protocol follow-up procedures
- Known allergy to warfarin or aspirin

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02628899
United States, California | |
Sutter Health System | |
Sacramento, California, United States, 95816 | |
Foundation for Cardiovascular Medicine | |
San Diego, California, United States, 92121 | |
United States, District of Columbia | |
MedStar Washington Hospital Center | |
Washington, District of Columbia, United States, 20010 | |
United States, Georgia | |
WellStar Kennestone Hospital | |
Marietta, Georgia, United States, 30060 | |
United States, Maine | |
Maine Medical Center | |
Portland, Maine, United States, 04102 | |
United States, New Jersey | |
The Valley Hospital | |
Ridgewood, New Jersey, United States, 07450 | |
United States, New York | |
Stony Brook Hospital | |
Stony Brook, New York, United States, 11794 | |
United States, Oklahoma | |
St. John Health System | |
Tulsa, Oklahoma, United States, 74104 | |
United States, Rhode Island | |
Miriam Hospital | |
Providence, Rhode Island, United States, 02906 | |
United States, Virginia | |
Henrico Doctors' Hospital | |
Richmond, Virginia, United States, 23229 | |
VCU Medical Center | |
Richmond, Virginia, United States, 23298 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Megan Rowland, Program Manager, Medstar Health Research Institute |
ClinicalTrials.gov Identifier: | NCT02628899 |
Other Study ID Numbers: |
Low Risk TAVR |
First Posted: | December 11, 2015 Key Record Dates |
Last Update Posted: | December 17, 2020 |
Last Verified: | December 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Aortic Valve Stenosis Constriction, Pathologic Pathological Conditions, Anatomical Heart Valve Diseases |
Heart Diseases Cardiovascular Diseases Ventricular Outflow Obstruction |